Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -52.81% | 114.30% | 52.00% | 186.33% | 466.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.81% | 114.30% | 52.00% | 186.33% | 466.14% |
| Cost of Revenue | 87.81% | 25.40% | -2.05% | -6.28% | -45.44% |
| Gross Profit | -81.71% | 963.65% | 319.64% | 1,609.00% | 710.87% |
| SG&A Expenses | 2.40% | -18.71% | 20.26% | 30.11% | 40.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.03% | -1.45% | 10.01% | 13.38% | -10.24% |
| Operating Income | -130.57% | 89.57% | 41.79% | 106.96% | 248.69% |
| Income Before Tax | -166.30% | 62.16% | 28.43% | -24.01% | 198.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -166.30% | 62.16% | 28.43% | -24.01% | 198.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -166.30% | 62.16% | 28.43% | -24.01% | 198.87% |
| EBIT | -130.57% | 89.57% | 41.79% | 106.96% | 248.69% |
| EBITDA | -130.52% | 89.63% | 41.83% | 106.98% | 249.02% |
| EPS Basic | -157.23% | 78.26% | 58.91% | 28.24% | 145.82% |
| Normalized Basic EPS | -157.21% | 79.96% | 58.92% | 89.90% | 145.56% |
| EPS Diluted | -162.56% | 78.26% | 58.91% | 28.24% | 142.49% |
| Normalized Diluted EPS | -164.10% | 79.96% | 58.92% | 89.90% | 140.67% |
| Average Basic Shares Outstanding | 15.87% | 73.99% | 74.25% | 72.82% | 115.78% |
| Average Diluted Shares Outstanding | 3.42% | 73.99% | 74.25% | 72.82% | 141.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |